04.21.11
Biogen Idec 1Q11
1Q Revenues: $1.2 billion (+9%)
1Q Earnings: $308.8 million (+40%)
Comments: Growth in the quarter was primarily driven by Tysabri revenues, up 15% to $251 million, and Avonex sales, up 8% to $642 million. Rituxan revenues from the company’s joint business arrangement with Elan were flat at $256 million for the quarter. Other product revenue in the quarter was flat at $13 million.
1Q Revenues: $1.2 billion (+9%)
1Q Earnings: $308.8 million (+40%)
Comments: Growth in the quarter was primarily driven by Tysabri revenues, up 15% to $251 million, and Avonex sales, up 8% to $642 million. Rituxan revenues from the company’s joint business arrangement with Elan were flat at $256 million for the quarter. Other product revenue in the quarter was flat at $13 million.